Meshalkin Research Institute of Pathology of Circulation
meshalkin.ruTotal trials
118
Active
6
Phase 3
19
Total enrollment
25,344
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 2 of 2 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Warfarin | — | — | — | 5 | |||
| Apixaban | — | — | — | — | 2 |
Next readouts
- 2028-01
Top conditions
- Atrial Fibrillation19
- Coronary Artery Disease13
- Ischemic Heart Disease7
- Cardiac Surgery6
- Paroxysmal Atrial Fibrillation6
- Coronary Artery Stenosis4
- Superficial Femoral Artery Occlusion4
- Coronary Atherosclerosis4
Frequently asked questions about Meshalkin Research Institute of Pathology of Circulation
- How many clinical trials does Meshalkin Research Institute of Pathology of Circulation have on ClinicalTrials.gov?
- Meshalkin Research Institute of Pathology of Circulation is listed as the lead sponsor on 118 clinical trials in ClinicalTrials.gov, 6 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Meshalkin Research Institute of Pathology of Circulation's trials are in Phase 3?
- 19 of Meshalkin Research Institute of Pathology of Circulation's trials are in Phase 3, spread across 2 active drug programs.
- What therapeutic areas does Meshalkin Research Institute of Pathology of Circulation focus on?
- Meshalkin Research Institute of Pathology of Circulation's most-studied conditions on ClinicalTrials.gov are Atrial Fibrillation, Coronary Artery Disease, Ischemic Heart Disease, Cardiac Surgery, Paroxysmal Atrial Fibrillation.
- When are Meshalkin Research Institute of Pathology of Circulation's next clinical trial readouts?
- Meshalkin Research Institute of Pathology of Circulation has 1 upcoming primary-completion readout tracked here; the soonest is “Apixaban VS Warfarin in AF Pts First Three Months After Repair or BIO AVR MVR”, expected around 2028-01.